Early MiSeq Users Say Data Quality Matches HiSeq; Cite Speed as Advantage for Range of Applications | GenomeWeb

By Julia Karow

This article has been updated to correct Tristan Orpin's title. He is chief commercial officer, not chief operating officer of Illumina.

As Illumina prepares to ship its MiSeq desktop sequencer more broadly, early-access customers are saying they are happy with their data and are considering using the instrument for a variety of applications that call for speed and moderate throughput.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.